COMPANY HISTORY

Xi'an Taikomed Pharmaceutical — Company History

Founded in 2011 and recognized as a Shaanxi Province SRDI SME in 2024 — 15 years of dedication to pharmaceutical R&D, 40+ milestones charting a CRO's path from startup to industry leader

Five-Phase Growth Journey

Foundation & Startup

2011 - 2013

Jun 2011

Company officially incorporated in Xi'an High-tech Zone

Apr 2012

"Guiqi Yangxue Dispersible Tablets" won 3rd Prize at the 3rd "Hi-tech Cup" Innovation & Invention Competition

Dec 2012

Recognized as Shaanxi Province AAA Credit Enterprise

Mar 2013

"Artificial Cultivation of Asarum sieboldii" won Ankang City 1st Prize for Science & Technology

Jun 2013

Certified as Shaanxi Province Sci-Tech Private Enterprise

Dec 2013

Certified as Xi'an Municipal Sci-Tech Private Enterprise

Qualification & Platform Building

2014 - 2016

Sep 2014
Awarded "High-Tech Enterprise" certification Core Credential

Dec 2014
Approved as "Shaanxi Postdoctoral Innovation Base" Provincial Platform

Dec 2014

Xi'an Jiaotong University Postdoctoral Training Base inaugurated

Dec 2014

"Jiefuya" recognized as Shaanxi Famous Trademark

Dec 2015

Angel round investment from Xike Angel Fund

Jan 2015

Joined Xi'an SME Federation as Vice President Unit

Jan 2016

Multiple Northwest University bases launched (postdoc training, master's/undergraduate practice, industry-academia-research)

Jan 2016

Co-established "Microscale Drug Delivery Engineering Lab" with Northwest University

Aug 2016

3rd Prize at the 5th China Innovation & Entrepreneurship Competition (Shaanxi Division)

2016
Completed corporate restructuring into joint-stock company Milestone

Rapid Growth & Capitalization

2017 - 2019

Jul 2017
Initiated first global innovative drug TKMGS series anti-tumor research Innovative Drug

Aug 2017

Excellence Award at the 6th China Innovation & Entrepreneurship Competition

Sep 2017

Selected for Xi'an NEEQ (National Equities Exchange and Quotations) candidate list

Oct 2017

High-Tech Enterprise re-certification approved

2018

Generic drug consistency evaluation product passed NMPA on-site inspection with zero deficiencies

Nov 2018

ISO 9001 Quality Management System certified

Dec 2018
Listed on Shaanxi Equity Exchange Trading Board (Code: 600033) Capital Milestone

2019
Recognized as Xi'an "Gazelle Enterprise" High Growth

Jun 2019

Ranked among China's Top 20 Pharmaceutical R&D Companies

Jun 2019

Xi'an High-tech Zone IP Advantage Enterprise

Nov 2019

3rd Prize at the 8th China Innovation & Entrepreneurship Competition

Dec 2019

Shenzhen MAH (Marketing Authorization Holder) transformation & service platform established

Achievement & Expansion

2020 - 2021

★ BREAKTHROUGH MILESTONE

July 2020 — Domperidone tablets passed NMPA consistency evaluation, becoming the first product in Shaanxi Province to pass consistency evaluation and win volume-based procurement bidding. This milestone marked Taikomed's strategic shift from a "contract R&D service provider" to an "innovation output engine."

Jul 2020
Domperidone tablets passed consistency evaluation — first in Shaanxi to both pass evaluation and win VBP bidding Historic Breakthrough

Nov 2020

"Xi'an Municipal Sustained-Release Formulation Engineering Center" certified

Dec 2020

High-Tech Enterprise re-certification approved

2021

Suzhou Innovative Medical Device R&D headquarters established

Mar 2021

ISO 9001 / ISO 14001 / ISO 45001 triple-system certification achieved

Apr 2021

Nifedipine SR tablets (Type II) passed NMPA consistency evaluation

May 2021

Huaiqihuang Granules and Huaier Granules process change projects filed with Jiangsu MPA

Continuous Upgrade & SRDI Recognition

2022 - 2024

Jun 2022

Xi'an Municipal Employment & Internship Base approved

Jul 2022

Donepezil HCl tablets passed NMPA consistency evaluation

Jun 2023
Pharmaceutical Formulation R&D Center inaugurated R&D Upgrade

Aug 2023

Xi'an Modified New Drug / Advanced Formulation Platform established

Oct 2023
Awarded Qinchuangyuan "Three Platforms" Demonstration — Achievement Transformation "Accelerator" Provincial Platform

Dec 2023

High-Tech Enterprise re-certification approved

Mar 2024

Awarded "Shaanxi Creativity Brand"

Jun 2024

ISO 9001 / ISO 14001 / ISO 45001 triple-system re-certified

Jun 2024
Led Xi'an Municipal Sci-Tech Program: Advanced Sustained-Release Formulation R&D for Chemical Drugs Government Program

Jul 2024
Recognized as "Shaanxi New R&D Institution" Provincial Designation

Aug 2024
Recognized as "Shaanxi Province SRDI SME" Authoritative Certification

15 Years of Technical Excellence, Empowering Every Molecule

From generic consistency evaluation to innovative drug R&D, from sustained-release formulations to TCM development — Taikomed delivers complete discovery-to-market pathways through six core technology platforms and full-process CRO capabilities.

Explore Our Core Technologies →